Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash & Equivalents (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Cash & Equivalents data on record, last reported at $83.2 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 418.07% year-over-year to $83.2 million; the TTM value through Sep 2025 reached $83.2 million, up 418.07%, while the annual FY2024 figure was $23.4 million, 57.7% up from the prior year.
  • Cash & Equivalents reached $83.2 million in Q3 2025 per ABEO's latest filing, down from $163.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $163.9 million in Q2 2025 and bottomed at $4.7 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $33.4 million, with a median of $17.6 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: plummeted 87.19% in 2022, then surged 458.46% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $38.8 million in 2021, then tumbled by 62.52% to $14.6 million in 2022, then rose by 1.76% to $14.8 million in 2023, then soared by 57.7% to $23.4 million in 2024, then soared by 256.3% to $83.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $83.2 million in Q3 2025, $163.9 million in Q2 2025, and $84.5 million in Q1 2025.